Entrada Therapeutics (TRDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Platform overview and scientific differentiation

• EEV platform enables efficient endosomal escape and delivery of oligonucleotides, improving muscle targeting for diseases like DMD and DM1.

• EEVs show higher efficiency than conventional biologics, with up to 50% endosomal escape.

• The approach is applicable to multiple diseases, with current focus on DMD, DM1 (with Vertex), and inherited retinal diseases.

Clinical development and data insights

• DMD programs target exons 44, 45, 50, and 51, with exon 44 in multiple ascending dose studies and cohort 2 and 3 planned.

• Early clinical data show strong safety profile, with no significant adverse events or toxicity observed.

• Functional benefit was observed early in exon 44 cohort 1, despite lower-than-expected dystrophin increases.

• Updated modeling using juvenile NHP data suggests higher doses in cohort 2 should achieve double-digit dystrophin levels.

• Cohort 2 (12 mg/kg) and open-label extension data are expected by year-end, focusing on safety and functional benefit.

Competitive landscape and market positioning

• DMD remains a large, under-penetrated market with high unmet need; data quality and safety are key differentiators.

• Competitors like Sarepta, Avidity, and NS Pharma have faced safety and efficacy challenges, leaving room for new entrants.

• Entrada's approach offers dosing flexibility and potential for less frequent administration, especially in exon 45 (every six weeks).

• Patient and investigator enthusiasm is high, with expanded access requests and positive Data Monitoring Committee feedback.